WuXi Biologics Achieves Eighth Consecutive CDMO Leadership Awards Recognition

WuXi Biologics Receives CDMO Leadership Awards for Eight Consecutive Years

On March 23, 2025, WuXi Biologics, a prominent player in the global Contract Research, Development, and Manufacturing Organization (CRDMO) sector, proudly announced its remarkable achievement of receiving the 2025 CDMO Leadership Awards in the 'Biologics - Global' category. This prestigious recognition has been granted to WuXi Bio for not just one, but multiple facets of excellence, including 'Best Scientific Expertise', 'Best Seamless Delivery Across Phases', and 'Best Innovative Approach to Technology and Process Execution'. This achievement emphasizes WuXi Biologics' unyielding commitment to innovation and quality in the biologics manufacturing field.

Winning the CDMO Leadership Award for the eighth consecutive year serves as a testament to WuXi Biologics' dedication to developing integrated technology platforms aimed at revolutionizing the biologics discovery, development, and manufacturing processes. The organization's commitment is particularly evident in its significant reduction of development time for monoclonal antibody projects, which has been shrunk to a record 9 months, with a stunning achievement of completing an autoimmune disease-related project in just 6 months.

One of the key advancements attributed to WuXi's success is the use of single-use technology (SUT), which allowed the company to scale its manufacturing capabilities from 4,000 liters to 16,000 liters across its global facilities. Notably, this expansion has been attained while maintaining an impressive 99% success rate from 2022 to 2024. Remarkably, the production costs associated with SUT technology remain competitive with traditional stainless steel systems, thus enhancing WuXi Biologics' market position.

The sustained success is underlined by WuXi's world-class quality assurance systems that have led to a perfect 100% success rate during pre-approval inspections (PAIs). The company has impressively passed over 40 inspections initiated by various global regulatory bodies, including 22 conducted by the FDA and EMA.

Dr. Chris Chen, the CEO of WuXi Biologics, expressed gratitude for the recognition, stating, "We are honored to receive the CDMO Leadership Award for the eighth consecutive year. This achievement not only signifies the trust that our global partners place in us but also reflects the relentless dedication of our exceptional team. Our ongoing commitment drives us to ensure that life-saving treatments are swiftly and effectively delivered to market—benefiting patients worldwide."

The CDMO Leadership Awards are presented by Outsourced Pharma and Life Science Leader, with 210 CDMOs evaluated on their performance based on authoritative third-party research. The awards celebrate top companies across four categories: Biologics, Cell and Gene Therapy, Small Molecule API, and Small Molecule Dosage Form, serving both Global and International territories.

About WuXi Biologics
WuXi Biologics (stock code 2269.HK) stands at the forefront of the global CRDMO landscape, dedicated to providing end-to-end solutions that empower partners in discovering, developing, and manufacturing biologics—from conception to commercialization. With over 12,000 skilled professionals stationed in strategic locations like China, the U.S., Ireland, Germany, and Singapore, WuXi leverages its profound expertise and technological capabilities to deliver efficient and cost-effective solutions for biologics discovery, development, and manufacturing. By the end of 2024, the organization was actively managing 817 integrated client projects, with 21 dedicated to commercial manufacturing tasks (excluding COVID CMO projects).

Moreover, WuXi Biologics places a significant emphasis on sustainability, considering it as a cornerstone for long-term business success. The company continually advocates for green technology innovations, delivering advanced end-to-end Green CRDMO solutions for its global partners while striving for excellence in Environmental, Social, and Governance (ESG) standards. With the mission to create shared value, WuXi actively collaborates with all stakeholders to foster positive social and environmental impacts, promoting responsible practices throughout its value chain.

For further insights into WuXi Biologics, visit www.wuxibiologics.com.